USFDA concludes inspection of Indoco Remedies’ testing facility with zero observation
The inspection was carried out from April 08, 2026 to April 10, 2026
The United States Food and Drug Administration (USFDA) has completed Pre-Approval Inspection at Indoco Remedies’ testing facility in Chhatrapati Sambaji Nagar, Maharashtra. The inspection was carried out from April 08, 2026 to April 10, 2026, and concluded with zero form 483 observations.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
